Welcome to our dedicated page for Aim Immunotech SEC filings (Ticker: AIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AIM ImmunoTech Inc. (AIM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include annual reports on Form 10‑K, quarterly reports on Form 10‑Q, current reports on Form 8‑K, registration statements such as Form S‑1 and S‑1/A, proxy statements on Schedule 14A, and notifications of late filing on Form 12b‑25.
Through its filings, AIM ImmunoTech describes its business as an immuno-pharma company focused on research and development of therapeutics for cancers, viral diseases, and immune-deficiency disorders, with flagship products Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa. Registration statements and prospectuses detail capital-raising transactions, including offerings of common stock, pre‑funded warrants, Class E and Class F warrants, and rights offerings involving Series G Convertible Preferred Stock and warrants. These documents outline terms such as subscription rights, exercise prices, and use of proceeds.
Current reports on Form 8‑K capture material events, such as entry into a Note Purchase Agreement for an unsecured promissory note with an institutional investor, the closing of public offerings, the filing of corporate charter documents, and the release of corporate presentations. Filings also describe exchange listing matters, including temporary suspension of trading on the NYSE American, trading on the OTC Pink under a different symbol, and subsequent reinstatement on the NYSE American under the AIM symbol.
Investors can review notifications of late filing, such as Form 12b‑25, which explain delays in filing periodic reports and provide preliminary estimates of changes in revenues and net loss. Definitive proxy statements (DEF 14A) provide information on director elections, advisory votes on executive compensation, auditor ratification, and the company’s status as a smaller reporting company.
On Stock Titan, AIM ImmunoTech’s filings are updated as new documents are released on EDGAR. AI-powered summaries help explain the key points of lengthy filings, including risk factor discussions, financing structures, and governance proposals, so that readers can more quickly understand what each 10‑K, 10‑Q, 8‑K, or registration statement means for the company.
AIM ImmunoTech Inc. (NYSE American: AIM) has filed Amendment No. 1 to its Form S-3 shelf registration statement, seeking authorization to issue up to $100 million of securities. The registration covers a wide variety of instruments—including common and preferred stock, debt securities (senior, senior subordinated or subordinated, convertible or non-convertible), warrants, purchase contracts, subscription rights, depositary shares and units—allowing management to access capital “from time to time” and in multiple tranches.
The company is classified as a non-accelerated filer and a smaller reporting company; it is not an emerging growth company. AIM’s common stock last traded at $9.50 on 23 June 2025. Specific terms (pricing, size, use of proceeds, underwriting arrangements) will be detailed in future prospectus supplements when individual offerings are launched.
Because the filing is a shelf registration under Rule 415, the statement enables AIM to move quickly when market conditions are favorable. However, the document also cautions investors that the information is preliminary and subject to change until the SEC declares the registration effective. Standard risk disclosures and forward-looking-statement safe-harbor language are included, and investors are directed to the company’s latest 10-K and subsequent filings for detailed risk factors.
Key takeaways for investors:
- Financing flexibility: Up to $100 million aggregate offering amount across multiple security types.
- Dilution potential: Common-equity issuance could dilute existing shareholders, depending on the mix ultimately chosen.
- Timing unknown: Securities may be issued “from time to time” after effectiveness; no immediate issuance timetable is provided.
- No earnings data: The filing does not include current operating results or guidance; it strictly pertains to capital-markets authority.
AIM ImmunoTech received a warning notification from NYSE American on June 17, 2025, regarding non-compliance with minimum stockholders' equity requirements. The company reported a stockholders' deficit of -$3.9 million as of March 31, 2025, falling short of the required:
- $4.0 million minimum for companies with losses in 3 of 4 recent fiscal years
- $6.0 million minimum for companies with losses in 5 most recent fiscal years
This follows a previous warning from December 17, 2024. The NYSE American has accepted AIM's compliance plan, giving the company until June 11, 2026 to meet requirements. Trading continues under symbol "AIM" without interruption, and the warning does not affect business operations or SEC reporting requirements. The company's stock resumed trading on NYSE American on June 17, 2025.